|
|
|
|
|
Dimitris Papadopoulos and Vangelis D. Karalis
Sample size is a key factor in bioequivalence and clinical trials. An appropriately large sample is necessary to gain valuable insights into a designated population. However, large sample sizes lead to increased human exposure, costs, and a longer time f...
ver más
|
|
|
|
|